Leqembi Wins Full FDA Approval as First Anti-Amyloid Antibody for Alzheimer’s

In the summer’s most highly anticipated regulatory decision, the FDA on Thursday greenlit Eisai and Biogen’s Leqembi (lecanemab) as the first anti-amyloid antibody—and the first disease-altering drug—for Alzheimer’s disease to win traditional approval.